The FDA has announced the recall of one brand of a popular type 2 diabetes drug, metformin, over a potentially cancer-causing impurity.
Viona Pharmaceuticals, Inc. is voluntarily recalling 23 lots of Metformin Hydrochloride Extended-Release Tablets due to the presence of the probable carcinogen NDMA.
The pharmaceutical company also recalled two lots of metformin in June 2021, citing the exact same carcinogenic impurity.
Check your medicine cabinet: Viona Pharmaceuticals, Inc. is recalling several lots of the popular medication Metformin Hydrochloride Extended-Release Tablets, USP 750 mg (often used to treat type 2 diabetes) over a potentially cancer-causing impurity.
The recall impacts 23 lots of Viona’s metformin drug, which likely contains unacceptable levels of the impurity N-nitrosodimethylamine (NDMA), per the Food and Drug Administration’s (FDA) January 12 announcement. NDMA is an environmental contaminant classified as a probable human carcinogen, the FDA says. Testing revealed the impurity in one lot, and the statement indicates that the rest are likely affected, too. No adverse events have been reported yet.
The 23 recalled metformin lots are packaged in bottles of 100 pills and have expiration dates between June 2022 and January 2023. They were shipped to distributors nationwide. You can find the full list of recalled lots here. Multiple pharmaceutical companies manufacture metformin, but this recall affects only Viona’s products.
. . .
This article originally appears at Yahoo!Life. To read the full article, click here .